Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma (MM).
The drugs involved in this study are:
- Dendritic Cell/MM Fusion vaccine (DC/MM vaccine)
- Nivolumab, an immunotherapy drug
A Phase II Trial of Vaccination with Dendritic Cell (DC)/Myeloma Fusions in Combination with Nivolumab in Patients with Relapsed Multiple Myeloma
- ClinicalTrials.gov Identifier: NCT03782064
- Protocol Number: 18-280
- Principal Investigator: Myrna Nahas
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required